KSL10 Antibody

What is BCL10 and why is it important in immunological research?

BCL10 is a key mediator protein that bridges CARD domain-containing proteins to immune activation. It plays essential roles in both adaptive and innate immune signaling pathways. BCL10 functions by channeling signals downstream of CARD domain-containing proteins (CARD9, CARD11, and CARD14) to activate NF-kappa-B and MAP kinase p38 (MAPK11-14) pathways. These pathways are crucial for the expression of genes encoding pro-inflammatory cytokines and chemokines . Understanding BCL10 is fundamental for researchers investigating immune response mechanisms, particularly those related to inflammation, apoptosis, and immune cell activation.

What are the known functional domains of BCL10?

BCL10 contains a CARD (caspase recruitment domain) at its N-terminus, which is critical for protein-protein interactions with other CARD-containing proteins. Through CARD-CARD interactions, BCL10 is recruited by homooligomerized CARD domain-containing proteins that form a nucleating helical template. This interaction promotes BCL10 polymerization, leading to the subsequent recruitment of MALT1 and formation of the CBM (CARD-BCL10-MALT1) complex . This complex is pivotal for downstream signaling that activates various immune response pathways.

How does BCL10 contribute to signaling pathways?

BCL10 contributes to signaling pathways through:

• Activation of NF-kappa-B: Following formation of the CBM complex, BCL10 helps trigger NF-kappa-B activation

• Activation of MAP kinase p38 pathways (MAPK11, MAPK12, MAPK13, MAPK14)

• Promotion of pro-inflammatory cytokine and chemokine gene expression

• Mediation of apoptosis signals

• Facilitation of pro-caspase-9 maturation

These activities position BCL10 as a central mediator in immune cell function and inflammatory responses.

How does BCL10 interact with different CARD proteins in adaptive versus innate immunity?

BCL10 exhibits differential interactions with CARD proteins depending on the immune pathway:

In antifungal immunity, CARD9 activation leads to BCL10 recruitment, which is essential for defending against fungal pathogens . In contrast, CARD11-mediated BCL10 activation occurs downstream of T-cell and B-cell receptor signaling, promoting adaptive immune responses . These different interaction patterns allow BCL10 to serve as a versatile mediator across multiple immune response mechanisms.

What is the role of BCL10 in the CBM signalosome complex formation?

In the CBM (CARD-BCL10-MALT1) signalosome complex, BCL10 serves as the critical bridging component. The process follows a specific sequence:

• CARD domain-containing proteins (CARD9/11/14) undergo homooligomerization upon upstream receptor activation

• These oligomerized CARD proteins form a nucleating helical template

• BCL10 is recruited via CARD-CARD interaction with these templates

• BCL10 polymerization occurs, creating a scaffold

• MALT1 is subsequently recruited to this scaffold

• The complete CBM complex activates downstream NF-kappa-B and MAP kinase pathways

This multi-step assembly process represents a sophisticated signaling mechanism that ensures appropriate immune response activation only when triggered by specific stimuli.

How do mutations in BCL10 affect immune signaling and pathological conditions?

Mutations in BCL10 can significantly impact immune signaling with various pathological consequences. Although the search results don't provide specific mutation data, research indicates that BCL10 dysregulation has been implicated in multiple disorders including:

• B-cell lymphomas/leukemias (as suggested by its alternative name "B-cell lymphoma/leukemia 10")

• Immunodeficiency disorders affecting both innate and adaptive immunity

• Inflammatory disorders from inappropriate immune activation

• Impaired antifungal immunity when BCL10-CARD9 signaling is disrupted

Researchers investigating these conditions should consider detailed mutation analysis of the CARD domain and BCL10 polymerization regions to understand the molecular mechanisms of disease.

What are the best experimental approaches for studying BCL10 protein interactions?

When studying BCL10 protein interactions, researchers should consider these methodological approaches:

• Co-immunoprecipitation (Co-IP): The BCL10 antibody [EP606Y] has been validated for immunoprecipitation, making it suitable for identifying BCL10 binding partners in different immune cell types .

• Proximity Ligation Assay (PLA): For detecting in situ interactions between BCL10 and CARD proteins or MALT1.

• Bimolecular Fluorescence Complementation (BiFC): For visualizing BCL10 interactions in living cells.

• FRET/FLIM Analysis: For measuring real-time interactions and conformational changes in the BCL10-containing complexes.

• Mass Spectrometry Following IP: For identifying novel interaction partners in different immune contexts.

Each approach offers distinct advantages, and combining multiple methods provides more robust evidence of protein-protein interactions.

How should researchers optimize immunohistochemistry protocols for BCL10 detection?

For optimal BCL10 detection using immunohistochemistry:

• Fixation: Use 10% neutral buffered formalin for 24-48 hours; overfixation may mask epitopes.

• Antigen Retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is recommended.

• Antibody Selection: The rabbit monoclonal antibody [EP606Y] has been validated for IHC-P applications .

• Dilution Optimization: Begin with manufacturer's recommended dilution (check specific product datasheet) and optimize based on tissue type.

• Detection System: A polymer-based detection system often provides better signal-to-noise ratio than avidin-biotin methods.

• Controls: Include positive controls (lymphoid tissues) and negative controls (primary antibody omission).

• Counterstaining: Light hematoxylin counterstaining allows better visualization of BCL10 positive cells.

Follow these guidelines while adapting to your specific tissue and research question requirements.

What considerations are important when designing flow cytometry experiments with BCL10 antibody?

When designing flow cytometry experiments to detect BCL10:

• Cell Preparation: Since BCL10 is an intracellular protein, proper fixation and permeabilization are critical. The BCL10 antibody [EP606Y] has been validated for intracellular flow cytometry .

• Fixation Options:

  • For co-staining with surface markers: Fix with 0.5-2% paraformaldehyde after surface staining

  • For intracellular staining only: Consider methanol-based fixation for better epitope accessibility

• Permeabilization: Test both saponin-based (0.1-0.5%) and Triton X-100 (0.1%) to determine optimal signal.

• Antibody Concentration: Titrate to determine optimal concentration that maximizes positive signal while minimizing background.

• Controls:

  • Isotype controls for nonspecific binding

  • Positive controls (cells known to express BCL10)

  • Negative controls (cells lacking BCL10 expression)

• Multiparameter Considerations: When combining with other markers, ensure compensation is properly set up for spectral overlap.

These methodological details will help ensure reproducible and interpretable flow cytometry results when studying BCL10 expression patterns.

How can researchers address non-specific binding when using BCL10 antibody?

Non-specific binding is a common challenge in antibody-based applications. When working with BCL10 antibody, consider these troubleshooting approaches:

• Increase Blocking Stringency: Use 5% BSA or 5-10% normal serum from the species in which the secondary antibody was raised.

• Antibody Validation: Verify that your BCL10 antibody [EP606Y] recognizes the correct epitope through Western blot analysis before other applications .

• Dilution Optimization: Test multiple antibody dilutions to find the optimal concentration that maintains specific signal while reducing background.

• Pre-absorption Controls: Pre-incubate the antibody with recombinant BCL10 protein to confirm binding specificity.

• Secondary Antibody Selection: Choose highly cross-adsorbed secondary antibodies to minimize cross-reactivity.

• Sample Preparation: Ensure complete permeabilization for intracellular targets while maintaining cellular structure.

Each of these strategies tackles different aspects of non-specific binding, and combining approaches may be necessary for optimal results.

What are the challenges in distinguishing BCL10 activation states in research samples?

Distinguishing between inactive and activated BCL10 presents significant challenges:

• Phosphorylation Analysis: BCL10 undergoes multiple phosphorylation events during activation. Consider using:

  • Phospho-specific antibodies (if available)

  • Phos-tag™ SDS-PAGE to detect mobility shifts

  • Mass spectrometry to identify specific phosphorylation sites

• Polymerization Detection: Activated BCL10 forms polymeric structures.

  • Native PAGE can help visualize these higher-order structures

  • Size-exclusion chromatography can separate monomeric from polymeric forms

  • Confocal microscopy can detect BCL10 puncta formation in stimulated cells

• Co-localization Studies: Activated BCL10 relocates to form complexes with CARD proteins and MALT1.

  • Immunofluorescence co-localization analysis with CARD9/11/14 and MALT1

  • Subcellular fractionation followed by Western blotting

• Downstream Signaling: Measure NF-κB activation as a proxy for BCL10 activity:

  • IκBα degradation analysis

  • NF-κB nuclear translocation

  • NF-κB-dependent gene expression

These complementary approaches provide a more comprehensive picture of BCL10 activation status.

How should researchers interpret conflicting BCL10 expression data across different experimental platforms?

When faced with conflicting BCL10 expression data across platforms:

• Epitope Considerations: Different antibodies recognize different epitopes. The rabbit monoclonal [EP606Y] targets a specific epitope that may be differently accessible in various applications .

• Sample Preparation Effects:

  Method	Potential Impact on BCL10 Detection
  Formalin fixation	May mask certain epitopes
  Freezing	Better epitope preservation but poorer morphology
  Denaturation (WB)	Exposes epitopes hidden in native conformation
  Native conditions (IP)	Maintains protein-protein interactions but may hide epitopes

• Validation Strategy:

  • Use multiple antibodies targeting different BCL10 epitopes

  • Employ orthogonal methods (mRNA expression, proteomics)

  • Include genetic models (knockout, knockdown) as controls

  • Consider cell-type specific expression patterns

• Data Integration Approach:

  • Weigh evidence from multiple techniques

  • Consider biological context and experimental conditions

  • Use statistical methods to integrate datasets

  • Report discrepancies transparently in publications

How might BCL10 research intersect with detoxification pathways in immune cells?

An emerging area of interest is the potential intersection between BCL10 signaling and cellular detoxification pathways:

• Xenobiotic Response: While BCL10 functions primarily in immune signaling, cellular responses to xenobiotics involve many of the same pathways (NF-κB, MAP kinases) that BCL10 activates . Research could investigate whether BCL10 signaling affects the expression of detoxification genes in immune cells exposed to environmental toxins.

• Oxidative Stress Response: Both immune activation and detoxification processes involve managing oxidative stress. The role of BCL10 in regulating antioxidant response elements could be explored, particularly in the context of immune cells dealing with both pathogen challenges and environmental toxins .

• Integration with Cytochrome P450 Systems: Investigating potential crosstalk between BCL10-mediated immune responses and cytochrome P450-dependent detoxification processes could reveal new understanding of how immune cells balance defense and detoxification functions .

This intersection represents an underexplored area where immune signaling meets environmental response mechanisms.

What novel techniques are emerging for studying BCL10 dynamics in real-time?

Recent technological advances offer new opportunities for studying BCL10 biology:

• CRISPR-based Tagging: Endogenous tagging of BCL10 with fluorescent proteins allows real-time visualization without overexpression artifacts.

• Optogenetic Control: Light-inducible BCL10 oligomerization systems to precisely control CBM complex formation temporally and spatially.

• Super-resolution Microscopy: Techniques like STORM and PALM can resolve BCL10 filament formation at nanometer resolution, providing insights into polymerization dynamics.

• Live-cell Biosensors: FRET-based sensors that detect BCL10 conformational changes or protein-protein interactions in living cells.

• Single-cell Analysis: Combining flow cytometry with transcriptomics to correlate BCL10 activation with gene expression patterns at the single-cell level.

These emerging approaches will enable researchers to move beyond static snapshots to understand the dynamic behavior of BCL10 in immune signaling.